Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 92 of 92 matching drugs for KMT2D — including drugs targeting any of its 18 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
olaparib PARP1 SSL via PARP1 yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
afatinib ERBB2 SSL via ERBB2 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
lapatinib ERBB2 SSL via ERBB2 yes 2
pembrolizumab, sonidegib SMO SSL via SMO 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
alvocidib, docetaxel CDK9 SSL via CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK9 SSL via CDK9 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib SMO SSL via SMO 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 SSL via ERBB2 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib SMO SSL via SMO 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 SSL via ERBB2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 SSL via ERBB2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
cetuximab, trastuzumab ERBB2 SSL via ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 SSL via ERBB2 1
db-1310, trastuzumab, osimertinib ERBB2 SSL via ERBB2 1
diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib SMO SSL via SMO 1
disitamab vedotin, tucatinib ERBB2 SSL via ERBB2 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 SSL via ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 SSL via ERBB2 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) CHEK1 SSL via CHEK1 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) CHEK2 SSL via CHEK2 1
enzastaurin, lomustine CHEK1 SSL via CHEK1 1
enzastaurin, lomustine CHEK2 SSL via CHEK2 1
enzastaurin, temozolomide, radiation therapy CHEK1 SSL via CHEK1 1
enzastaurin, temozolomide, radiation therapy CHEK2 SSL via CHEK2 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 SSL via ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 SSL via ERBB2 1
gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib SMO SSL via SMO 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim SMO SSL via SMO 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 SSL via ERBB2 1
lapatinib, chemoradiation, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 SSL via ERBB2 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 SSL via ERBB2 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 SSL via ERBB2 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab ERBB2 SSL via ERBB2 1
palbociclib, afatinib ERBB2 SSL via ERBB2 1
pazopanib, lapatinib ERBB2 SSL via ERBB2 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab ERBB2 SSL via ERBB2 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine ERBB2 SSL via ERBB2 1
tesevatinib ERBB2 SSL via ERBB2 1
tirelizumab, trastuzumab, docetaxel, s1, oxaliplatin ERBB2 SSL via ERBB2 1
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment ERBB2 SSL via ERBB2 1
trastuzumab, pertuzumab, paclitaxel, carboplatin ERBB2 SSL via ERBB2 1
trilaciclib CDK9 SSL via CDK9 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab ERBB2 SSL via ERBB2 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo ERBB2 SSL via ERBB2 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 SMO SSL via SMO 1
vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study SMO SSL via SMO 1
zanidatamab, tislelizumab, trastuzumab, capecitabine, oxaliplatin, cisplatin, 5-fluorouracil ERBB2 SSL via ERBB2 1
zongertinib, trastuzumab deruxtecan, trastuzumab emtansine ERBB2 SSL via ERBB2 1
afatinib dimaleate ERBB2 SSL via ERBB2 yes 0
dacomitinib ERBB2 SSL via ERBB2 yes 0
glasdegib SMO SSL via SMO yes 0
glasdegib maleate SMO SSL via SMO yes 0
lanreotide ERBB2 SSL via ERBB2 yes 0
lanreotide acetate ERBB2 SSL via ERBB2 yes 0
lapatinib ditosylate ERBB2 SSL via ERBB2 yes 0
neratinib ERBB2 SSL via ERBB2 yes 0
neratinib maleate ERBB2 SSL via ERBB2 yes 0
niraparib PARP1 SSL via PARP1 yes 0
niraparib tosylate PARP1 SSL via PARP1 yes 0
pertuzumab ERBB2 SSL via ERBB2 yes 0
rucaparib PARP1 SSL via PARP1 yes 0
rucaparib camsylate PARP1 SSL via PARP1 yes 0
sonidegib SMO SSL via SMO yes 0
sonidegib phosphate SMO SSL via SMO yes 0
talazoparib PARP1 SSL via PARP1 yes 0
talazoparib tosylate PARP1 SSL via PARP1 yes 0
trastuzumab deruxtecan ERBB2 SSL via ERBB2 yes 0
vandetanib ERBB2 SSL via ERBB2 yes 0
vismodegib SMO SSL via SMO yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.